Belief BioMed enters exclusive partnership with Grand Life Sciences for haemophilia A treatment

Glaukos launches Epioxa to advance incision-free treatment for keratoconus

Sanofi's venglustat receives FDA Breakthrough Therapy designation for type 3 Gaucher disease

Sentynl Therapeutics and PRG S&T enter licensing agreement for potential HGPS treatment

CMIC agrees agentic AI partnership with Bluenote

Biofrontera reports Phase 2b data for Ameluz photodynamic therapy in acne vulgaris treatment

Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD

AstraZeneca and Daiichi Sankyo's Enhertu receives US priority review for post-neoadjuvant HER2-positive early breast cancer

Egetis receives US notice of allowance for MCT8 deficiency composition patent

Ipsen withdraws tazverik across all markets following safety concerns in lymphoma trial

Halozyme reports US FDA approval of TECVAYLI in combination with DARZALEX FASPRO for relapsed/refractory multiple myeloma

Foresee Pharmaceuticals receives positive CHMP opinion for CAMCEVI 21 mg

Great Novel Therapeutics' GNTbm-38 approved by US FDA for Phase I trial

Johnson & Johnson reports US FDA approval of TECVAYLI plus DARZALEX FASPRO for RRMM

Airiver Medical's Airiver Pulmonary DCB receives US FDA Breakthrough Device Designation